Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial Meeting Abstract
| Authors: | Necchi, A.; Roumiguié, M.; Esen, A. A.; Lebret, T.; De Wit, R.; Shore, N. D.; Bajorin, D. F.; Krieger, L. E. M.; Kandori, S.; Uchio, E. M.; Seo, H. K.; Boormans, J.; Kamat, A. M.; Singer, E. A.; Grivas, P.; Nishiyama, H.; Nam, K.; Kapadia, E.; Van den Sigtenhorst-Fijlstra, M.; Kulkarni, G. S. |
| Abstract Title: | Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial |
| Meeting Title: | 2023 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2023 Feb 16-18 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-20 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.6_suppl.LBA442 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: LBA442 -- Source: Cinahl |
